Why a Standard PET-CT Is the Wrong Tool Here
Understanding why prostate cancer requires protein-targeted molecular imaging rather than glucose metabolic imaging:
If you have read about PET scans, you have probably read about FDG PET-CT — the glucose-based scan used across most cancers. Prostate cancer is the notable exception. Most prostate cancers are slow-metabolising and are not strongly FDG-avid. Booking a standard FDG PET-CT for prostate cancer is, in most situations, using the wrong tool.
Standard FDG PET-CT (Glucose Metabolism)
Metabolic Principle: Tracks glucose consumption. Because most prostate cancers metabolise glucose slowly, FDG PET-CT frequently under-detects disease, yielding false negatives in early recurrence or low-volume metastasis.
PSMA PET-CT (Protein Receptor Targeting)
Targeting Principle: Binds directly to Prostate-Specific Membrane Antigen (PSMA), expressed heavily on prostate cancer cell surfaces. Can identify tiny deposits of only a few millimetres in normal-sized lymph nodes.
💡 Targeting vs. Metabolism
PSMA PET-CT does not measure cell hunger; it targets a molecular lock-and-key on the cell membrane. This allows nuclear medicine physicians to spot physically tiny cancer deposits that CT scans report as normal size and bone scans miss completely.
The Two Situations Where PSMA PET-CT Is Used
Evidence-based indications for requesting a PSMA PET-CT scan:
Biochemical Recurrence — Rising PSA After Treatment
This is the most common reason for referral. PSA rises after radical prostatectomy or radiotherapy, conventional CT and bone scans are clear, and the clinical team needs to locate the source: is it confined locally to the prostate bed (where salvage radiation can cure it) or spread to distant sites?
📊 Clinical Impact: Published data shows PSMA PET-CT identifies true positive lesions in ~64% of patients with negative conventional imaging — altering treatment plans in 54% to 76% of cases.
Primary Staging in High-Risk Prostate Cancer
Before deciding on major surgery or radical radiotherapy in high-risk newly diagnosed disease, PSMA PET-CT determines whether disease has already metastasised beyond the pelvis.
🏆 proPSMA Trial Evidence: The landmark proPSMA trial demonstrated markedly superior accuracy over conventional CT + bone scan, using less total radiation and preventing unnecessary non-curative operations.
Your PSA Level Matters — Detection Rate Ladder
Every patient asks: “Will the scan find anything?” Here is what published clinical trials indicate:
| PSA Level (ng/mL) | Approximate PSMA Detection Rate | Clinical Interpretation & Action |
|---|---|---|
| < 0.2 ng/mL | Around 38% | Low yield; microscopic disease may be present below scan resolution threshold. |
| 0.2 – 0.5 ng/mL | Around 36% | Moderate yield. Oncologist weighs PSA doubling time before scanning. |
| 0.5 – 1.0 ng/mL | Intermediate (Rising) | Detection rate increases steadily as tumor burden reaches scan sensitivity. |
| 1.0 – 2.0 ng/mL | High Yield | Strong likelihood of identifying distinct focal recurrent lesions. |
| > 2.0 ng/mL | Around 97% | Near-certain lesion detection and precise anatomical localization. |
| > 5.0 ng/mL | Around 97% | Definitive mapping for systemic or targeted radioligand therapy planning. |
⚠️ The Clinical Timing Dilemma
Scan too early: The yield is low, increasing the chance of a negative scan while microscopic disease remains.
Scan too late: Disease may spread further, narrowing the window for curative salvage therapy.
Ask your specialist: “Given my PSA level and doubling speed, is now the right time for a PSMA scan or should we monitor?”
What PSMA PET-CT Cannot Do
An honest clinical guide to the limitations and diagnostic pitfalls of PSMA imaging:
🚫 Not a Screening Test
PSMA PET-CT is never used to screen asymptomatic men. Screening relies on PSA blood tests, clinical exam, MRI, and biopsy. PSMA imaging is strictly for confirmed or recurrent disease.
🔬 Non-Expressing Tumours
A minority of aggressive, neuroendocrine, or poorly differentiated prostate cancers express little to no PSMA. In these specific variants, FDG PET-CT or MRI may be required instead.
📍 Non-Prostate PSMA Expression
PSMA expression occurs naturally in salivary glands, kidneys, liver, bowel, and nerve ganglia. Experienced nuclear medicine reporting is mandatory to distinguish benign uptake from cancer.
⚖️ A Finding, Not a Verdict
A bright spot on PET is an image finding, not an absolute final verdict. Your uro-oncology team interprets scan results alongside PSA velocity, prior pathology, and clinical context.
Ga-68 vs F-18 PSMA: Tracer Differences & Booking Rules
Why tracer logistics dictate strict scheduling rules for your PET appointment:
Gallium-68 PSMA (Ga-68)
Half-life ~68 mins: Generator-produced in small batches specifically for scheduled patients on the day of the scan. Zero margin for missed appointment times.
Fluorine-18 PSMA (F-18)
Half-life ~110 mins: Cyclotron-produced with slightly longer shelf-life, offering enhanced resolution and minor scheduling flexibility.
🚫 Crucial Warning: Do Not Accept Substitutes
If your doctor prescribes a PSMA PET-CT, do NOT accept a standard FDG PET-CT as a substitute. They use completely different mechanisms. A standard FDG scan will miss most prostate cancer recurrences!
Preparing for Your PSMA PET-CT Scan
Step-by-step instructions for scan day at Karauli Diagnostics:
Fasting Generally Not Required
Unlike FDG PET scans, PSMA does not compete with blood glucose. Fasting is usually unnecessary, but confirm specific instructions with our team during booking.
Drink Plenty of Water
Stay well hydrated before and after the scan. The tracer is excreted via the kidneys and bladder; good hydration flushes background activity for clearer images.
Empty Bladder Right Before Scan
You will be asked to void your bladder immediately prior to entering the scanner room. A full bladder obscure the prostate bed area.
Bring Complete Records
Bring your prescription, complete PSA history (trend and doubling time), biopsy/pathology reports, surgery records, and prior CT/MRI discs.
Disclose ADT / Hormone Treatment
Inform the team if you are on Androgen Deprivation Therapy (ADT). Hormone therapy alters PSMA receptor expression levels and influences scan timing.
PSMA PET-CT Cost in Varanasi & Ayushman Bharat
Transparent pricing, tracer arrangement requirements, and government scheme eligibility:
| Scan Type | Karauli Diagnostics Rate | Key Notes & Logistics |
|---|---|---|
| PSMA PET-CT Scan | Contact Helpline (Specialist Tracer) | Requires advance radiotracer synthesis & dedicated slot booking. |
| Standard FDG PET-CT (Comparison) | Market Avg ~₹24,000 | Routine glucose-based imaging for general oncology. |
💳 Ayushman Bharat PM-JAY Coverage
PET-CT imaging is covered under Ayushman Bharat PM-JAY for approved cancer treatment packages at empanelled hospital network facilities. Check eligibility before paying privately.
A Note on PSMA-Targeted Theranostics (Lu-177)
How diagnostic PSMA PET-CT connects to advanced radioligand therapy:
You may have read about Lutetium-177 PSMA (Lu-177) therapy — a targeted radiopharmaceutical treatment that delivers destructive radiation directly to PSMA-expressing cancer cells.
The Diagnostic Link: A PSMA PET-CT scan is mandatory prior to Lu-177 therapy to verify that all metastatic lesions exhibit high PSMA receptor density. In this context, the scan acts as a selection test for treatment suitability. Karauli Diagnostics performs diagnostic PSMA PET-CT imaging; radioligand therapy is administered at specialized tertiary cancer centers.
Where to Get a PSMA PET-CT Scan in Varanasi
Serving patients across Varanasi, Jaunpur, Mirzapur, Ghazipur, and eastern Uttar Pradesh across our 5 diagnostic centres:
Sankat Mochan Branch (Main PET & PSMA PET-CT Unit)
B. 36/4-27, Ramapuri Colony, Near Sankat Mochan Temple, Saket Nagar Colony, Varanasi, Uttar Pradesh – 221005
Equipped with United Imaging uMI 550 TOF PET-CT Scanner.
Bhojubeer Branch
S.2/326 E-3A, Plot No. 18/1, Gilat Bazar, Bhojubeer, Varanasi, Uttar Pradesh – 221002
Google Maps DirectionsManduadih Branch
Shop No. 1, MS Commercial Complex, Manduadih Varanasi, Uttar Pradesh – 221005
Google Maps DirectionsMaldahiya Branch
C21/30, A1-A2 Pishachmochan Road Near Ganga Palace Maldhaiya, Varanasi, Uttar Pradesh – 221002
Google Maps DirectionsAwaleshpur Branch
Amra Chauraha, Above Grihasthi Supermarket, Varanasi, Uttar Pradesh – 221106
Google Maps DirectionsKey Takeaways
Essential points to remember for patients and referring physicians:
FDG is the wrong tool for prostate cancer: Most prostate tumours are slow-metabolising. PSMA targets cell surface proteins rather than glucose metabolism.
PSA level dictates detection yield: Detection rates range from ~38% at PSA <0.2 ng/mL to ~97% at PSA >2.0 ng/mL. PSA doubling speed guides clinical timing.
Advance tracer scheduling is mandatory: PSMA radiotracers have short half-lives and are synthesized for specific patient slots. Call helpline for lead times.
Frequently Asked Questions
Clear answers to common questions about PSMA PET-CT scanning:
A PET-CT scan using a tracer that binds to prostate-specific membrane antigen, a protein expressed at high levels on most prostate cancer cells. Because it targets a protein rather than measuring metabolism, it can detect prostate cancer deposits of only a few millimetres — including in lymph nodes a CT would report as normal in size.
Most prostate cancers are not strongly FDG-avid, so a standard glucose-based PET-CT can substantially under-detect them. PSMA targets a protein specific to prostate cells instead. If your prescription specifies PSMA, a standard FDG PET-CT is not an equivalent substitute.
It often does. Published data indicates that in patients with negative conventional imaging, PSMA PET-CT identified true positive lesions in around 64% of cases. The chance of detection depends strongly on your PSA level — roughly 38% at PSA below 0.2 ng/mL, rising to around 97% above 2 ng/mL.
There is no single threshold, and it is a clinical judgement. Detection rates are low at very low PSA levels but rise steeply as PSA increases. Scanning too early risks a negative result; waiting too long may narrow the window for curative salvage treatment. PSA doubling time often matters as much as the absolute value. Discuss timing with your urologist or oncologist.
No. At low PSA levels a negative scan is common and does not exclude microscopic disease. Additionally, a minority of prostate cancers express little or no PSMA — these tend to be more aggressive or neuroendocrine-type — so a negative scan in that context is not reassurance. Interpret the result with your treating team.
No. It is not used to find prostate cancer in men who have not been diagnosed. Screening involves PSA testing and clinical examination, with MRI and biopsy where indicated. PSMA PET-CT is used after diagnosis, for staging or suspected recurrence.
Generally no — unlike FDG PET-CT there is no glucose competition, so fasting is typically not required. You will be asked to stay well hydrated and to empty your bladder before imaging. Confirm the specific protocol when you book.
Typically yes, because the tracer is specialist and must be arranged in advance. Call 70689 70689 for the current rate and lead time. Check your Ayushman card eligibility before paying privately.
Usually not. PSMA tracers have short half-lives and are prepared for specific patients, so advance booking is required. Ask about the lead time and the cancellation policy when you call.
Yes, always. Androgen deprivation therapy can affect PSMA expression, which influences both the timing of the scan and how the images are interpreted. Bring your full treatment history.
Peer-Reviewed Research & Clinical Guidelines
Clinical trials and medical literature cited in this article:
- Primary Staging Randomized Trial: proPSMA Trial — Hofman et al., The Lancet (2020)
- Detection Rates & Clinical Impact: PSMA PET/CT in contemporary prostate cancer management — PubMed Research
- Biochemical Recurrence & Salvage: Diagnostic accuracy of 18F-PSMA-1007 PET/CT in biochemical recurrence — PMC Radiology Review
- Conventional Imaging Comparison: PSMA PET/CT versus conventional imaging in recurrence — Annals of Nuclear Medicine
Medically Reviewed by Nuclear Medicine Specialist
Consultant Nuclear Medicine Physician, Karauli Diagnostics · Published: 17 August 2026
This article is for general informational purposes and does not replace clinical consultation with your urologist or oncologist. Scan timing and interpretation are individualised clinical decisions.
Explore Related Oncology & Diagnostic Guides
• PET-CT Scan in Varanasi: Cost, Prep & What It Shows (Oncology Pillar Guide)
• Heart Test in Varanasi: Which One Do You Actually Need? (Pillar Guide)
• Diabetes and Heart Disease: What You Should Actually Screen For
• Heart Attack Under 40: What Indians Should Actually Know
• Lipid Profile Report: What Your Numbers Actually Mean
• Coronary Calcium Score: Blockage Before Symptoms
• CT Coronary Angiography: How to Prepare for Your Scan
• CT Coronary Angiography Cost in Varanasi (2026)
• 2D Echo vs ECG vs TMT: Which Heart Test Do You Need?